$24.05
8.59% yesterday
Nasdaq, Nov 15, 10:05 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Stock price

$24.05
-2.29 8.69% 1M
-0.06 0.25% 6M
-3.17 11.65% YTD
-1.10 4.37% 1Y
-62.39 72.18% 3Y
+5.30 28.27% 5Y
+5.30 28.27% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-2.26 8.59%
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Key metrics

Market capitalization $1.99b
Enterprise Value $1.23b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.51
P/S ratio (TTM) P/S ratio 5.70
P/B ratio (TTM) P/B ratio 2.51
Revenue growth (TTM) Revenue growth 328.73%
Revenue (TTM) Revenue $349.64m
EBIT (operating result TTM) EBIT $-182.67m
Free Cash Flow (TTM) Free Cash Flow $-145.37m
Cash position $925.76m
EPS (TTM) EPS $-1.76
P/E forward negative
P/S forward 42.98
EV/Sales forward 27.91
Short interest 19.45%
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

10x Buy
56%
8x Hold
44%

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
56%
Hold
44%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
350 350
329% 329%
100%
- Direct Costs 22 22
22% 22%
6%
328 328
512% 512%
94%
- Selling and Administrative Expenses 82 82
104% 104%
24%
- Research and Development Expense 406 406
6% 6%
116%
-161 -161
57% 57%
-46%
- Depreciation and Amortization 22 22
22% 22%
6%
EBIT (Operating Income) EBIT -183 -183
54% 54%
-52%
Net Profit -144 -144
54% 54%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London.
Neutral
Seeking Alpha
8 days ago
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market siz...
Neutral
Seeking Alpha
10 days ago
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kos...
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 436
Founded 2017
Website www.beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today